Constitutive IKK2 activation in intestinal epithelial cells induces intestinal tumors in mice

Katerina Vlantis,1 Andy Wullaert,1 Yoshiteru Sasaki,2,3 Marc Schmidt-Supprian,2,4 Klaus Rajewsky,2 Tania Roskams,2 and Manolis Pasparakis1

Many cancers display increased NF-κB activity, and NF-κB inhibition is known to diminish tumor development in multiple mouse models, supporting an important role of NF-κB in carcinogenesis. NF-κB activation in premalignant or cancer cells is believed to promote tumor development mainly by protecting these cells from apoptosis. However, it remains unclear to what extent NF-κB activation exhibits additional protumorigenic functions in premalignant cells that could be sufficient to induce spontaneous tumor development. Here we show that expression of constitutively active IκB kinase 2 (IKK2ca) in mouse intestinal epithelial cells (IECs) induced spontaneous tumors in aged mice and also strongly enhanced chemical- and Apc mutation-mediated carcinogenesis. IECs expressing IKK2ca displayed altered Wnt signaling and increased proliferation and elevated expression of genes encoding intestinal stem cell–associated factors including Ascl1, Olfm4, DLK1, and Bmi-1, indicating that increased IKK2/NF-κB activation synergized with Wnt signaling to drive intestinal tumorigenesis. Moreover, IECs expressing IKK2ca produced cytokines and chemokines that induced the recruitment of myeloid cells and activated stromal fibroblasts to become myofibroblasts, thus creating a tumor-promoting microenvironment. Taken together, our results show that constitutively increased activation of IKK2/NF-κB signaling in the intestinal epithelium is sufficient to induce the full spectrum of cell-intrinsic and stromal alterations required for intestinal tumorigenesis.

Introduction

The IκB kinase (IKK)/NF-κB signaling pathway controls the expression of many genes regulating immune and inflammatory responses, cell survival, and proliferation and is believed to be centrally involved in carcinogenesis. Many cancer cell lines, but also primary tumors, display constitutively increased NF-κB activity, and inhibition of NF-κB compromises the survival and growth of cultured cancer cells, suggesting that NF-κB is important for the survival of at least some types of tumors (1). Furthermore, NF-κB inhibition diminished tumor development in mouse models, supporting an important role for NF-κB in carcinogenesis (2–6).

IKK2/IKKB-mediated NF-κB activation was proposed to provide a link between inflammation and carcinogenesis by acting both in cancer cells and in cells of the microenvironment to promote tumor development (7, 8). IKK2 ablation in myeloid cells reduced the expression of cytokines and growth factors supporting tumor growth and diminished tumor development in the azoxymethane/dextran sulfate sodium (AOM/DSS) mouse model of carcinogen-initiated inflammation-associated colon cancer (5). In addition, NF-κB activation in cancer-associated fibroblasts was recently shown to be important for skin carcinogenesis by coordinating the expression of fibroblast-derived proinflammatory factors promoting macrophage recruitment, neovascularization, and tumor growth (9). These studies demonstrated that NF-κB promotes carcinogenesis by acting in cells of the tumor microenvironment to induce the expression of factors supporting tumor growth. In line with its well-established prosurvival functions, IKK2 ablation in colonic or gastric epithelial cells reduced the incidence of AOM/DSS-induced colon cancer (5) and carcinogen N-methyl-N-nitrosourea–induced (MNU-induced) gastric cancer (6). In addition, NF-κB inhibition by expression of an IκBα superrepressor (IκBα-SR) or by ablation of p65/RelA in lung epithelial cells led to spontaneous tumor development (12), while IKK2 ablation in melanocytes protected mice from oncogenic Ras–induced melanoma development (2).

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2011;121(7):2781–2793. doi:10.1172/JCI45349.
Mutations leading to constitutive NF-κB activation have been found in several cancers (1, 15–17), suggesting that persistent activation of NF-κB could be a critical step in tumor development, although the mechanisms by which cell-intrinsic NF-κB activation promotes tumorigenesis remain incompletely understood. Most importantly, it remains unclear whether constitutive NF-κB activation is sufficient to induce spontaneous tumor development in vivo. Here we used a transgenic mouse model expressing constitutively active IKK2 specifically in intestinal epithelial cells (IECs) to study the mechanisms by which constitutively increased NF-κB activation affects intestinal tumorigenesis. Our results show that persistent NF-κB activation strongly synergizes with chemical and genetic models of intestinal carcinogenesis to induce tumors in both the colon and the small intestine (SI). Most importantly, mice expressing constitutively active IKK2 in IECs spontaneously developed tumors in the colon and the SI, demonstrating that persistent activation of IKK2/NF-κB signaling in IECs is sufficient to induce intestinal tumorigenesis.

**Results**

Constitutive IKK2/NF-κB activation in IECs induced mild inflammation in the colon and SI. To study in vivo the epithelial-intrinsic role of NF-κB in intestinal tumorigenesis, we generated mice expressing constitutively active IKK2 in IECs. Our results show that persistent NF-κB activation strongly synergizes with chemical and genetic models of intestinal carcinogenesis to induce tumors in both the colon and the small intestine (SI).
constitutively active IKK2 (IKK2ca) specifically in IECs by crossing mice carrying the R26-StopFLIkk2ca (IKK2caFL) allele (18) with villin-Cre transgenics (19). Homozygous mice expressing 2 copies of the R26-StopFLIkk2ca allele (IKK2caIEChom) expressed high levels of IKK2ca specifically in IECs (Figure 1, A and B; Supplemental Figure 1A and Supplemental Figure 2A; supplemental material available online with this article; doi:10.1172/JCI45349DS1) and showed increased NF-κB activation, as assessed by IkBα immunoblot of total protein extracts and by EMSA on nuclear extracts from colonic and SI primary epithelial cells (Figure 1, A and C, and Supplemental Figure 1B). Heterozygous mice carrying 1 copy of the R26-StopFLIkk2ca allele (IKK2caIEChet) expressed about half the levels of IKK2ca and also showed elevated NF-κB activation in IECs (Supplemental Figure 1). IKK2ca-expressing IECs showed normal levels of IKK1, NEMO, and p65, but increased expression of p100 and RelB, which are produced by NF-κB–regulated genes (Supplemental Figure 1A) (20, 21). IKK2caIEChom mice showed moderately reduced body weight (Supplemental Figure 2B), prompting us to assess whether they developed spontaneous intestinal disease. Endoscopic analysis of 7- to 9-week-old animals did not reveal signs of inflammation in the distal colon of IKK2caIEChom mice compared with littermate controls (Figure 1, D and E). Colon length did not

Figure 2

Immune cell infiltration and increased cytokine and chemokine expression in the gut of IKK2caIEChom mice. (A) Immunohistochemical staining for Gr1 and F4/80 reveals increased numbers of granulocytes and macrophages, respectively, in colonic and SI cross sections of 6-week-old IKK2caIEChom mice. In the SI of IKK2caIEChom mice, F4/80-positive cells accumulated around the crypts, while in control mice, macrophages were mainly found in the villi. (B and C) qRT-PCR analysis shows enhanced expression of a subset of proinflammatory genes in the colon (B) and the ileum (C) of 7- to 8-week-old IKK2caIEChom mice (n ≥ 6 for each genotype; mRNA levels are presented as mean ± SD). (D) Immunohistochemical staining with antibodies recognizing α-SMA revealed the presence of increased numbers of activated myofibroblasts in colons of young (10 week old) and aged (1 year old) IKK2caIEChom mice compared with IKK2caFL littermates. Scale bars: 50 μm.
To determine whether constitutive NF-κB activation in IECs affects inflammation-associated colon cancer, we assessed AOM/DSS-induced carcinogenesis in Iκκ2caIEChom and control mice (Figure 4A). Since Iκκ2caIEChom mice were very sensitive to DSS treatment, we applied a modified protocol including only 1 short cycle of treatment with low DSS concentration (1.5% DSS for 3 days). This treatment induced severe weight loss associated with intestinal bleeding and diarrhea in Iκκ2caIEChom but not in control mice (Figure 4A and data not shown). Moreover, endoscopic analysis performed 26 days after AOM injection revealed signs of severe colitis in Iκκ2caIEChom but not in Iκκ2caIEChom mice (Figure 4B). Endoscopy on day 65 revealed that all Iκκ2caIEChom but none of their Iκκ2caIEChom littermates, had developed multiple tumors in the distal colon (Figure 4C), which displayed histological characteristics typical of mucus-producing adenomas with advanced dysplasia (Figure 4D) and in some cases progressed to adenocarcinomas invading the submucosa (Figure 4E). Thus, IEC-specific expression of Iκκ2ca had a strong protumorigenic effect resulting in the development of multiple broad-based colon adenomas even under a very mild AOM/DSS protocol that was not sufficient to induce tumors in control mice. The extreme sensitivity of Iκκ2caIEChom mice to DSS-induced inflammation most likely contributed to the strongly enhanced tumorigenesis observed in these animals upon AOM/DSS treatment. Greten et al. showed previously that epithelial-specific ablation of Iκκ2 also sensitized mice to DSS-induced injury resulting in increased colon inflammation; however, these mice showed reduced AOM/DSS-induced tumor development (5). Therefore, while both inhibition and increased activation of Iκκ2 in the intestinal epithelium sensitized mice to DSS, resulting in increased colon inflammation, they differentially affected AOM/DSS-induced colon cancer development, suggesting that Iκκ2 exerts important cell-intrinsic functions in IECs that are critical for tumorigenesis.

To uncouple the potential epithelial intrinsic protumorigenic functions of Iκκ2ca from its effects in DSS-induced colitis, we investigated whether constitutive Iκκ2/NF-κB activity also affects carcinogenesis induced by repeated AOM injections in the absence of DSS, a model of carcinogen-induced colon cancer that does not depend on inflammation-mediated tumor promotion (23, 24). Iκκ2caIEChom and Iκκ2caIEChom littermates received 5 weekly injections of AOM, and colon cancer development was evaluated 13 weeks after the first injection. Whereas Iκκ2caIEChom controls did not develop intestinal tumors with this protocol, all Iκκ2caIEChom mice developed multiple broad-based adenomas with hyperplasia and early dysplasia in the colon, but also showed hyperplastic crypts with shortened villus structures in the SI (Figure 4F). Thus, constitutively increased Iκκ2 activity in IECs strongly synergized with AOM-induced mutagenesis to induce intestinal tumorigenesis.

Constitutive Iκκ2/NF-κB activation strongly synergized with Wnt signaling to promote intestinal tumorigenesis. Most intestinal cancers display increased activation of the Wnt signaling pathway, and mutations activating Wnt signaling cause intestinal tumors in humans and mice (25). The adenomatous polyposis coli gene encoding the APC tumor suppressor, an essential component of the multiprotein complex negatively regulating β-catenin activation, is frequently mutated in human intestinal cancers, and APC mutations cause intestinal tumors in mice (25–28). To assess whether constitutive Iκκ2/NF-κB activity in IECs affects APC mutation–induced tumorigenesis, we crossed the Iκκ2caIEChom mice with Apc1638N mice, which bear a truncated Apc allele and spontaneously develop adenomatous polyps in the proximal part of the SI at an age of 6 to 9 months (29).
Endoscopic and macroscopic analysis of intestines from 4-month-old animals revealed the presence of multiple polyps in both the colon and the proximal half of the SI of Apc1638N/IKK2caIEChet mice (Figure 5A and data not shown). In contrast, only 2 out of 6 Apc1638N mice harbored 1 to 2 small polyps in the proximal SI, while none of the IKK2caIFL or IKK2caIEChet littermate controls showed intestinal tumors (Figure 5A). Histological analysis of colon sections revealed the presence of adenomas containing dysplastic crypts with undifferentiated multilayered epithelium in Apc1638N/IKK2caIEChet mice (Figure 5B). In addition, SI sections showed the presence of adenomatous polyps containing aberrantly shaped dysplastic crypts with stratified undifferentiated epithelium in Apc1638N/IKK2caIEChet mice (Figure 5B). Tumors in the colon and SI from Apc1638N/IKK2caIEChet mice showed strongly increased proliferation as assessed by Ki67 immunohistochemistry (IHC) (Figure 5C). In addition, all epithelial cells in dysplastic crypts from Apc1638N/IKK2caIEChet mice showed strong nuclear staining for the transcription factor Sox9, a β-catenin/TCF4-target gene that is normally highly expressed in crypt stem cells and at lower levels in transit amplifying (TA) cells, Paneth cells, and enteroendocrine cells, but is absent from differentiated absorptive enterocytes (refs. 30, 31, and Figure 5D). In contrast, epithelial cells in Apc1638N or IKK2caIEChet mice did not show increased proliferation or Sox9 expression compared with those in control animals (Figure 5D and Supplemental Figure 4). Thus, constitutive IKK2 activation in IECs strongly synergized with the Apc1638N mutation to enhance tumorigenesis, resulting in early development of highly proliferative dysplastic adenomatous lesions displaying increased β-catenin activation in Apc1638N/IKK2caIEChet mice.

**Spontaneous tumor development in the colon and SI of aged IKK2caIEChom mice.** Our results showed that epithelial-specific expression of IKK2ca strongly enhanced tumorigenesis in different inflammation-dependent, carcinogen-induced, and genetic models of intestinal cancer, suggesting that constitutively increased IKK2 activity in IECs promotes tumor development by affecting fundamental cellular processes important for intestinal carcinogenesis. To address whether constitutively increased IKK2 activity was sufficient to induce the spontaneous development of intestinal tumors, we followed a cohort of IKK2caIEChom and littermate control mice over a period of 12 months and assessed tumor development by endoscopy and postmortem macroscopic and histological examination. During the course of this experiment, we noticed that a fraction of the aging IKK2caIEChom animals showed pronounced weight loss and diarrhea, occasionally accompanied by rectal prolapse and bleeding, and were sacrificed before the age of 12 months. Histopathological analysis of tissues from these IKK2caIEChom animals showed thickening of the bowel wall in both the SI and colon and revealed the presence of hyperplastic and sometimes dysplastic crypts, indicating that IKK2ca expression induces intestinal tumors (data not shown). Endoscopic analysis revealed colon inflammation in nearly all IKK2caIEChom mice that reached 1 year of age and the presence of large tumors in the distal colon in about 50% of these animals (Figure 6, A and B). Histologically, these tumors showed a thickened inflamed mucosa with hyperplastic aberrant crypt growth and in some cases also dysplastic crypts characterized by loss of differentiation and epithelial...
stratification (Figure 6C). From 17 IKK2caIEChom mice examined at the age of 1 year, we found early hyperplastic adenomas in 10 animals and in 6 of those we detected also more advanced adenomatous lesions with epithelial dysplasia. Histological analysis of the SI revealed lesions with abnormal crypt architecture and increased crypt numbers indicating epithelial hyperproliferation in 7 out of 14 IKK2caIEChom mice, 4 of which also showed the growth of adenomatous polyps with signs of early dysplasia (Figure 6C). Ki67 staining revealed strong hyperproliferation of epithelial cells in tumors from the colon and SI of IKK2caIEChom mice (Figure 6D). In addition, all epithelial cells in dysplastic crypts showed strong expression of Sox9, indicating activation of β-catenin in these cells (Figure 6D). Collectively, these results demonstrate that constitutively increased IKK2 activity in premalignant IECs was sufficient to induce the spontaneous development of tumors displaying increased proliferation and β-catenin activation in the colon and to a lesser extent also in the SI of IKK2caIEChom mice.
Figure 5

Heterozygous IKK2ca expression in IECs strongly enhances tumorigenesis in Apc1638N mice and results in early tumor formation in the colon and the SI. (A) Macroscopic analysis of intestines from 4-month-old mice showed that all Apc1638N/IKK2caIEChet mice examined ($n = 11$) had developed at least 1 macroscopically visible tumor in the colon and also multiple clearly identifiable polyps in the proximal half of the SI. Littermate Apc1638N/IKK2caFL mice ($n = 6$) did not show colon tumors, while only 2 out of 6 animals examined bore 1 or 2 small polyps in the pyloric region of the SI. IKK2caFL ($n = 9$) and IKK2caIEChet ($n = 11$) mice did not show tumors in either the colon or the SI. (B) Histological analysis of colon sections from Apc1638N/IKK2caIEChet mice revealed the presence of tumors showing hyperplastic and dysplastic crypts with multilayered undifferentiated epithelium. Histological analysis of proximal SI sections from Apc1638N/IKK2caIEChet mice revealed the growth of polyps that harbored aberrantly shaped, dysplastic crypts showing epithelial stratification and lack of differentiation. Histological analysis of colon and SI sections from IKK2caIEChet and IKK2caFL littermates did not reveal the presence of tumors. (C) Immunostaining for Ki67 revealed increased proliferation of epithelial cells in adenomas from the colon and SI of Apc1638N/IKK2caIEChet mice, whereas Apc1638N/IKK2caFL mice showed a normal Ki67 staining pattern. (D) Immunohistochemical analysis revealed strong Sox9 expression in all epithelial cells in colonic and SI tumors in Apc1638N/IKK2caIEChet mice. In contrast, Apc1638N/IKK2caFL mice showed normal Sox9 staining, with Sox9-positive IECs in the base of the crypts and the transit-amplifying compartment in both tissues. Scale bars: 50 μm.
Increased β-catenin activity and perturbation of the stem cell compartment in the intestine of IKK2_αIEChom mice. To investigate the early mechanisms by which IKK2α expression drives intestinal tumorigenesis, we examined colon and SI tissue from 8-week-old IKK2αIEChom animals for activation of the β-catenin pathway. Immunohistochemical analysis of β-catenin revealed increased presence of active β-catenin in both cytoplasmic and nuclear extracts from colon epicells from IKK2αIEChom mice (Figure 7A). Consistent with the increased β-catenin activation, immunostaining for Ki67 revealed increased epithelial cell proliferation in transgenic colon crypts with an extension of the Ki67-positive nuclei toward the lumen indicative for an expanded TA cell compartment (Figure 7B). Interestingly, all SI crypt epithelial cells were Ki67+ in IKK2αIEChom mice, in contrast to the well-defined proliferation pattern of control crypts where Ki67 stained TA cells and only occasionally cells in the base of the crypts, where Paneth cells and the rarely dividing intestinal epithelial stem cells are located (32, 33). In line with this observation, crypts in the SI and colon of IKK2αIEChom mice showed an expansion of the Sox9-expressing epithelial cell compartment, suggesting increased β-catenin transcriptional activity (Figure 7C). Despite the increased epithelial proliferation, the Wnt-regulated c-myc and cyclin D1 genes were not upregulated in IKK2α-expressing IECs (Supplemental Figure 5C). However, MMP7, also known to be transcriptionally regulated by β-catenin (34), was expressed at higher levels in epithelial cells from IKK2αIEChom mice (Supplemental Figure 5C). Therefore, some not all β-catenin target genes were induced in IKK2α-expressing IECs. Sox9 negatively regulates Wnt-induced expression of c-myc and cyclin D1 (35); therefore, increased Sox9 expression might be responsible for the fact these genes are not upregulated in IKK2α-expressing IECs.

SI crypts in IKK2αIEChom mice showed the expected Sox9 expression pattern with stem cells, identified as cells located at the bottom of the crypt characterized by a slim cytoplasmic rim and elongated triangular nuclei, and Paneth cells, identified by their small round nuclei and large cytoplasm, strongly stained with anti-Sox9 antibodies (36). In contrast, the Sox9 staining pattern in the SI from IKK2αIEChom mice did not allow the clear identification of Paneth cells or stem cells in crypt bases (Figure 7C). Furthermore, crypt fission events, which are thought to occur only upon stem cell duplication, were regularly observed in IKK2αIEChom but not in control mice. These observations indicated that the differentiation or proliferation status of crypt stem cells, which have been identified as the cells of origin of intestinal cancer (37), might be altered already in premalignant intestinal crypts of IKK2αIEChom mice. Indeed, analysis of genes known to be expressed in intestinal epithelial stem cells (31) showed strong upregulation of Ascl2 and Olfm4 and moderate increase in CD44 and Tnfrs19 expression in the colon from 7- to 8-week-old IKK2αIEChom mice (Figure 7D). Ascl2, CD44, and Bmi-1 were also upregulated in the SI from these animals (Figure 7E). Olfm4, Bmi-1, and CD44 were previously shown to be regulated by NF-κB (38–40), and we also found that the promoter of Ascl2 contains a consensus NF-κB site (data not shown), suggesting that constitutively increased IKK2α/NF-κB activity might directly regulate the intestinal stem cell compartment by inducing the expression of NF-κB target genes encoding stem cell–associated factors. The expression of DLK1 (also called Pref1), a protein that is best known for its role in preventing progenitor cell differentiation in different tissues (41) and has been implicated in colon carcinogenesis (42), was also strongly upregulated in both the colon and SI from IKK2αIEChom mice (Figure 7F). Thus, several stem cell–associated factors are upregulated in the intestine of IKK2αIEChom mice and could be implicated in the development of spontaneous tumors in this model.

Discussion

Many cancers display constitutive activation of NF-κB signaling, indicating that NF-κB activation is an important event during tumor development affecting fundamental cellular processes that are critical for carcinogenesis. NF-κB activation in early initiated or malignant tumor cells is believed to perform mainly antiapoptotic functions (17). However, it remains unclear whether constitutive NF-κB activation in premalignant cells performs additional protumorigenic functions that are critical for carcinogenesis. In this context, it is not known whether cell-intrinsic NF-κB activation is sufficient to induce spontaneous tumor development.

Here we show that expression of constitutively active IKK2 in IECs not only strongly synergizes with chemical and genetic models of intestinal carcinogenesis, but also is sufficient to induce the spontaneous development of tumors in both the colon and the SI. Our studies suggest that sustained IKK2 activation in IECs drives intestinal tumorigenesis by exerting both cell-intrinsic and paracrine functions. IKK2 activation in epithelial cells induced the expression of several proinflammatory cytokines and chemokines that are important for intestinal carcinogenesis. It is noteworthy that although IKK2α expression strongly activated NF-κB signaling in IECs, only a subset of the known NF-κB–regulated cytokines and chemokines were upregulated. For example, IL-6, a well-known NF-κB–inducible cytokine that has been implicated in colorectal carcinogenesis (43–45), was not upregulated in IKK2αIEChom mice. In contrast, TNF and IL-1β were upregulated in both the SI and colon of IKK2αIEChom mice, and given their important function in the regulation of intestinal inflammation and carcinogenesis (46, 47), they are likely to be implicated in IKK2α-mediated intestinal tumor development. The most highly upregulated gene in IKK2α-expressing IECs was CCL20, a chemokine that has been reported to induce tumor cell growth and migration in human colorectal cancer (48). Another chemokine that was highly induced in the intestine of IKK2αIEChom mice is Cxcl-16, which together with its receptor Cxcr6 has been suggested to promote inflammation-associated tumor development (49). Therefore, IKK2α expression in IECs induces the expression of specific cytokines and chemokines with important protumorigenic activities.

Increased numbers of macrophages and granulocytes, but not T or B lymphocytes, were detected in the mucosa of young mice, suggesting that increased cytokine and chemokine expression by IECs initiated an innate immune response driven by myeloid cells. Infiltrating macrophages were found mainly surrounding the base of the crypts in the colon and SI of IKK2αIEChom mice. Since intestinal tumors originate from crypt stem cells, increased myeloid cell infiltration in this area is likely to contribute to the spontaneous development of intestinal tumors in IKK2αIEChom mice by creating a microenvironment supporting tumor growth. In addition to immune cells, stromal fibroblasts that are activated to become myofibroblasts constitute an important component of the tumor-supporting microenvironment (50). We detected the presence of increased numbers of α-SMA–expressing activated myofibroblasts in close proximity with the IECs of both aged and young IKK2αIEChom mice, suggesting that stromal fibroblasts are activated already at a
very early stage and could contribute to intestinal tumor initiation and progression in this model. Cytokines secreted by IKK2ca-expressing IECs are likely to induce the differentiation of stromal fibroblasts to tumor-supporting myofibroblasts.

Indeed, proinflammatory cytokines such as IL-1β were previously shown to activate stromal fibroblasts to support tumor initiation and growth (9). Therefore, constitutive activation of IKK2/NF-κB signaling in IECs acts in a paracrine manner...
to induce the infiltration of myeloid cells and the activation of stromal fibroblasts, creating a microenvironment supporting tumor growth. However, it is unlikely that IKK2ca expression drives intestinal tumorigenesis only by inducing cytokine expression, as the chronic intestinal inflammation caused by increased TNF expression in a mouse model of severe Crohn disease was not sufficient to induce intestinal tumors (S1).

The Wnt signaling pathway controls normal epithelial homeostasis, and mutations activating Wnt signaling cause intestinal tumors in humans and mice (26, 52, 53). We therefore hypothesized that constitutive IKK2 activation in IECs might have an impact on Wnt signaling to induce intestinal tumorigenesis. Indeed, we found that IECs in IKK2caIEChom mice showed increased expression and activation of β-catenin already in a premalignant state, a surprising

Figure 7
Increased β-catenin activation, hyperproliferation, and elevated stem cell factor expression in IECs from IKK2caIEChom mice. (A) Immunoblot analysis on cytoplasmic and nuclear extracts from colonic IECs showed increased levels of β-catenin and active N terminally nonphosphorylated β-catenin in 8-week-old IKK2caIEChom compared with IKK2caFL mice. (B) Immunofluorescent staining for Ki67 reveals increased IEC proliferation in the colon of 10-week-old IKK2caIEChom mice, where the proliferating cells were extended toward the lumen. Whereas in control ileum, mainly the TA cells showed Ki67 staining, all crypt cells were Ki67+ in the ileum of IKK2caIEChom mice. (C) Immunohistochemical staining revealed increased numbers of Sox9-expressing IECs in the colon and SI of 10-week-old IKK2caIEChom compared with IKK2caFL mice. Paneth cells and stem cells were not identifiable with Sox9 staining in SI crypts from IKK2caIEChom mice. (D and E) qRT-PCR analysis showed increased expression of intestinal stem cell factors in the colon (D) and in the SI (E) of 7- to 8-week-old IKK2caIEChom compared with IKK2caFL littermates (n ≥ 6 per genotype; mRNA levels are presented as mean ± SD). (F) qRT-PCR analysis showed increased expression of DLK1 in the colon and in the ileum of 7- to 8-week-old IKK2caIEChom mice compared with IKK2caFL littermates (n ≥ 6 per genotype; mRNA levels are presented as mean ± SD). Scale bars: 50 μm.
result considering previous studies reporting that IKK2 negatively regulates β-catenin activity (54). Although the precise mechanisms by which constitutive IKK2/NF-κB signaling in IECs induces β-catenin activation are not fully understood at present, overexpression of IKK2ca could increase β-catenin activity by either cell-intrinsic or paracrine functions. β-catenin activation in tumors is not controlled solely by Wnt ligands or mutations activating Wnt signaling, but additional Wnt-independent cues from the microenvironment are also required for full activation of β-catenin signaling (52, 55). Indeed, stromal myofibroblasts were recently shown to regulate β-catenin activation in colon cancer cells via the secretion of factors not related to Wnt ligands (56). In addition, macrophages have been shown to regulate β-catenin activation in tumor cells by secreting cytokines such as TNF and IL-1β (56–59). Macrophage-produced TNF activated Wnt signaling by inducing GSK3β phosphorylation in an NF-κB–independent manner (57). Furthermore, IL-1β activated β-catenin via the NF-κB–dependent induction of PDK1/Akt-mediated phosphorylation of GSK3β (59). IKK activation was also required for GSK3β phosphorylation and β-catenin activation in response to progastrin stimulation (60). Thus, constitutive IKK2 activation in IECs might also activate β-catenin in a cell-intrinsic manner by inducing PDK1/Akt-mediated phosphorylation of GSK3β. In addition, since degradation of both β-catenin and IκB proteins is regulated by the β-TrCP E3 ubiquitin ligase (61), it is possible that high expression levels of constitutively active IKK2A inducing continuous phosphorylation and degradation of IκB proteins, as in the IECs of IKK2caBChom mice, reduces β-TrCP availability for β-catenin degradation and in this way indirectly increases β-catenin activity. The Wnt signaling pathway regulates the fate of intestinal crypt stem cells, which are the cells of origin of intestinal cancers (37, 62). We observed that all cells in the base of SI crypts, which in wild-type mice harbor rarely dividing stem cells and Paneth cells, stained strongly with Ki67 antibodies in IKK2caBChom mice, suggesting that the crypt stem cells show increased proliferation in IKK2caBChom mice. In addition, gene expression analysis in the intestine of IKK2caBChom mice revealed increased expression of a number of stem cell–specific genes including Ascl2, Olfm4, CD44, TnfRsF19, and Bmi-1. These alterations are likely to be linked with β-catenin activation in IECs from IKK2caBChom mice, since Ascl2, TnfRsF19, and CD44 are β-catenin target genes (31). However, Olfm4, Bmi-1, and CD44 are regulated by NF-κB (38–40). In addition, we found that the gene encoding Ascl2, a transcription factor controlling intestinal stem cell fate (31), contains an NF-κB consensus site in its promoter suggesting that NF-κB activation could also directly induce Ascl2 expression. In addition, DLK1 was strongly upregulated in IECs overexpressing IKK2caA. Although DLK1 has not been directly associated with intestinal crypt stem cells, it is known to prevent preadipocyte differentiation by inducing the expression of Sox5 and is thought to play a more general role in maintaining progenitor cells in different tissues in an undifferentiated state (41). Thus, the observed increase in Sox9 expression in IKK2ca-expressing IECs could be induced cooperatively by β-catenin and DLK1. DLK1 was also implicated in colorectal carcinogenesis (42), suggesting it could be directly implicated in intestinal tumorigenesis in IKK2caBChom mice. Alterations in the intestinal stem cell compartment have not been reported in mice with epithelial-specific inhibition of NF-κB (5, 22, 63), suggesting that impairment of NF-κB activity might not be sufficient to alter intestinal stem cell homeostasis. However, constitutively increased NF-κB activation, such as in IKK2caBChom mice or upon amplification of the Ikk2 genomic locus in human colorectal cancers (15), could affect the intestinal stem cell compartment and in this way contribute to intestinal tumorigenesis. In our experimental approach, IKK2ca is expressed under the control of the Rosa26 locus that drives strong expression in all cell types of the intestinal epithelium including crypt stem cells (64); therefore, we cannot address the specific contribution of stem cell–intrinsic NF-κB activation in intestinal tumorigenesis. Studies in new mouse models allowing stem cell–specific manipulation of NF-κB activity will be required to address the potential role of NF-κB in intestinal epithelial stem cells.

Taken together, our results presented here show that constitutive IKK2 activation in premalignant epithelial cells is sufficient to initiate and sustain the full spectrum of cell-intrinsic and microenvironmental alterations that are required for intestinal tumorigenesis. While IKK2ca expression strongly activated NF-κB, we cannot exclude that other NF-κB–independent functions induced by IKK2 contributed to intestinal tumorigenesis in this model. In addition to its well-established antiapoptotic function, IKK2 activation rendered tumor cells self-sufficient by providing them with the capacity to alter their microenvironment to support tumor growth. These findings provide experimental evidence that mutations activating IKK2/NF-κB signaling could have a causative role in carcinogenesis, although it remains to be investigated whether constitutive NF-κB activation is sufficient to induce tumor development in tissues other than the intestinal epithelium. However, a recent unbiased large scale genomic analysis of somatic copy number alterations in human cancers revealed that members of the NF-κB signaling pathway, including IKK2, were frequently amplified in different cancer types (15), supporting a fundamental tumor cell–intrinsic role of NF-κB in carcinogenesis.

Methods

Mice. R26IkK2caBChom (18), villinCre (19), and Apc1638N mice (29) have been described. Unless otherwise indicated, littermates carrying R26IkK2caBChom alleles, but not the villin-Cre transgene, served as control mice for the described experiments. Animals were housed in individually ventilated cages in a specific pathogen–free mouse facility at the University of Cologne. All animal studies were approved by local governmental authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany).

Mouse experiments. DSS (MP, MW 36000–50000) was provided in the drinking water. AOM was administered via intraperitoneal injections at 10 mg/kg. For endoscopy, mice were anesthetized with ketamine (Ratiopharm/Rompun (Bayer), and a high-resolution minendoscope, Coloview (Karl Storz), was used to determine the murine endoscopic index of colitis severity (murine endoscopic inflammatory colitis score [MEICS]) and to assess colonic tumorigenesis as previously described (65).

Histology. Tissues were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 4-μm sections. H&E-stained sections were scored in a blinded fashion for the amount of inflammation, tissue damage, and/or tumorigenesis. For IHC staining, paraffin sections were rehydrated and heat-induced antigen retrieval was performed either in 10 mM sodium citrate, 0.05% Tween-20, pH 6.0, or in 10 mM Tris; 1 mM EDTA, pH 9.0. Primary antibodies were anti-Ki67 (Dako), anti-FLAG (Sigma-Aldrich), anti-Gr1 (BD Biosciences – Pharmingen), anti-F4/80 (clone A3-1), anti-B220 (clone RA3-6B2), anti-CD3 (Abcam), anti-Sox9 (Millipore), anti-β-catenin (BD Biosciences – BD Transduction Laboratories). Biotinylated secondary antibodies, ABC Kit Vectastain Elite, and DAB substrate (PerkinElmer, Vector, and Dako) were used. Incubation times with DAB were equal for...
all samples. For immunofluorescence, Alexa Fluor 488–coupled antibodies (Invitrogen) were used; nuclei were counterstained with DAPI (Roche). Pictures were taken with a fluorescence microscope (DM5500; Leica) at the same exposure intensity and settings for all systems analyzed.

**IEC isolation and immunoblotting.** IECs were isolated by sequential incubation of intestinal tissue in 1 mM DTT and 1.5 mM EDTA solutions as described previously (66). For total extracts, cells were lysed in high-salt RIPA buffer (20 mM HEPES, pH 7.6; 350 mM NaCl; 20% glycerol; 1 mM MgCl₂; 0.5 mM EDTA; 0.1 mM EGTA; 1% NP-40) for 30 minutes on ice. For the preparation of cytoplasmic extracts, cells were lysed in hypotonic lysis buffer (10 mM HEPES, pH 7.6; 10 mM KCl; 2 mM MgCl₂; 0.1 mM EDTA) on ice, and the nuclear extract was recovered by lysis under high-salt conditions (50 mM HEPES, pH 7.8; 50 mM KCl; 300 mM NaCl; 0.1 mM EDTA; 10% glycerol). Protease inhibitor cocktail and PhosSTOP (Roche) were added prior to use. Protein extracts were separated by 10% SDS-PAGE and transferred to Immobilon-P PVDF membranes (Millipore). Membranes were probed with primary antibodies anti-IKK2 (rabbit monoclonal; Cell (rabbit; made in our laboratory; ref. 14), anti-IκBα (rabbit; Santa Cruz Biotechnology Inc.), and anti–lamin A/C (goat; Santa Cruz Biotechnology Inc.). Membranes were then incubated with secondary HRP-coupled antibodies (GE Healthcare and Jackson ImmunoResearch) and developed with chemiluminescence detection substrate (GE Healthcare and Thermo Scientific).

**EMSAs.** Nuclear IEC extracts were prepared as described previously (67). An NF-kB consensus probe (5'-AGTTGAGGGAGCTTCCCAGGC-3') was 5'-labeled with IR-Dyes (Li-Cor Biosciences) and detected with the Odyssey Infrared System.

**qRT-PCR.** Total RNA was extracted with Trizol Reagent (Invitrogen) and RNeasy Columns (QIAGEN), and cDNA was prepared with Superscript III cDNA-synthesis Kit (Invitrogen). qRT-PCR was performed with SYBR Green or TaqMan analysis (Applied Biosystems). Gapdh, Villin, and TATA-box binding protein (TBP) were used as reference genes.

**TagMan probes and primer sequences used for qRT-PCR.** TagMan probes were as follows: Cxcl1, Mm00433859_m1; Cxcl10, Mm00445228_m1; Cxcl16, Mm00469712_m1; Ccl20, Mm00444228_m1; TNF, Mm00443258_m1; MCP-1, Mm00441242_m1; IL-1β, Mm00433258_m1; IL-6, Mm00441690_m1; IL-12 p35, Mm00434165_m1; IL-12 p40, Mm99999067_m1; IL-23 p19, Mm00158984_m1; IL-17F, Mm00521423_m1; TGF-β1, Mm03024053_m1; Cox2, Mm00478374_m1; Ascl2, Mm01268891_g1; Olfn4, Mm01320260_m1; DLK1, Mm00494477_m1; Lgr5, Mm00438890_m1; CD133, Mm00477115_m1; Gapdh, Mm9999915_g1; TATA box binding protein, and Mm00446973_m1.

**Primary sequences for SYBR Green qRT-PCR were obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank/index.html):**

Bmi-1 for TATAAATCGTATGGATATAAAGC, rTATAAGTGGTACTGAGGGCC-3' was 5'-labeled with IR-Dyes (Li-Cor Biosciences) and detected with the Odyssey Infrared System.

**Acknowledgments.** We wish to thank C. Uthoff-Hachenberg, J. Pfeiffer, E. Mahlberg, D. Beier, J. Buchholz, B. Hueler, and B. Wolff for excellent technical assistance. We also thank Alan Clarke for valuable discussions. This work was supported by the European Commission FP7 program grant INFLA-CARE (EC contract number 223151) and by grants from the Deutsche Forschungsgemeinschaft to M. Pasparakis.

Received for publication October 10, 2010, and accepted in revised form April 6, 2011.

Address correspondence to: Manolis Pasparakis, Institute for Genetics, University of Cologne, Zülpicher Str. 47a, D-50674 Cologne, Germany. Phone: 49.221.470.1526; Fax: 49.221.470.5163; E-mail: pasparakis@uni-koeln.de.